Drug-induced anti-Ro positive subacute cutaneous lupus in a man treated with olmesartan

A 66-year-old man presented to the outpatient dermatology clinic with a chief complaint of a pruritic rash on his upper trunk and proximal upper extremities, which had been present for three weeks. Upon examination, he was found to have an erythematous, annular, and polycyclic eruption on the chest,...

Full description

Saved in:
Bibliographic Details
Published in:Dermatology online journal 2019-01, Vol.25 (12)
Main Authors: Gray, Taylor, Segars, Kelly, Farsi, Maheera, Ross, Risa, Miller, Richard
Format: Article
Language:English
Subjects:
Aged
Angiotensin II Type 1 Receptor Blockers - adverse effects
Antibodies, Antinuclear - blood
Dermatology
Humans
Hypertension - drug therapy
Imidazoles - adverse effects
Lupus
Lupus Erythematosus, Cutaneous - chemically induced
Lupus Erythematosus, Cutaneous - diagnosis
Lupus Erythematosus, Cutaneous - pathology
Male
Patients
Skin - pathology
Skin diseases
Tetrazoles - adverse effects
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 66-year-old man presented to the outpatient dermatology clinic with a chief complaint of a pruritic rash on his upper trunk and proximal upper extremities, which had been present for three weeks. Upon examination, he was found to have an erythematous, annular, and polycyclic eruption on the chest, upper back, and proximal extremities. A clinical diagnosis of subacute cutaneous lupus erythematosus (SCLE) was made. The patient was found to have a positive anti-nuclear antibody (ANA) in a speckled pattern and a positive anti-Ro antibody. A biopsy revealed an interface and lichenoid dermatitis with dermal mucin deposition, consistent with subacute cutaneous lupus erythematosus. The patient reported that he had recently been diagnosed with hypertension and began treatment with olmesartan, a potassium-sparing diuretic that blocks the angiotensin II receptor, commonly used as an antihypertensive or in patients with heart failure. Cutaneous reactions to olmesartan are rare and reported in
ISSN:1087-2108
1087-2108
DOI:10.5070/D32512046719